Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
vTv Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
VTVT
Nasdaq
2834
https://vtvtherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for vTv Therapeutics Inc
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
- Mar 19th, 2024 12:30 pm
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
- Mar 13th, 2024 12:00 pm
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
- Mar 4th, 2024 8:49 pm
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
- Mar 4th, 2024 1:00 pm
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
- Mar 1st, 2024 1:00 pm
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
- Feb 28th, 2024 1:00 pm
CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE
- Feb 22nd, 2024 9:00 pm
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update
- Nov 9th, 2023 9:30 pm
vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
- Nov 8th, 2023 1:00 pm
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
- Nov 2nd, 2023 12:00 pm
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
- Nov 1st, 2023 12:00 pm
One vTv Therapeutics Insider Raised Their Stake In The Previous Year
- Oct 19th, 2023 12:22 pm
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19
- Sep 27th, 2023 12:30 pm
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer
- Sep 26th, 2023 12:30 pm
3 Tumbling Stocks to Take a Chance On Now
- Sep 22nd, 2023 9:22 am
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA
- Sep 18th, 2023 12:30 pm
Is vTv Therapeutics Inc (VTVT) Modestly Undervalued?
- Aug 24th, 2023 4:35 pm
vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
- Aug 11th, 2023 8:30 pm
Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer
- Aug 10th, 2023 12:33 pm
vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline
- Jun 16th, 2023 12:00 pm
Scroll